Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The SPRY domain containing 4 pseudogene (ENSG00000254216) is a genomic region with high sequence similarity to the SPRYD4 protein coding gene but contains mutations or lacks transcriptional regulatory elements, preventing it from producing a functional protein. Pseudogenes, including SPRYD4 pseudogene, do not code for active proteins but may have regulatory impacts at the RNA level, such as decoy effects on microRNAs or participation in antisense regulation. SPRYD4 pseudogene is not considered a therapeutic target, nor is it involved directly in disease biology or biomarker selection. The parent SPRYD4 gene is a nuclear, ubiquitously expressed SPRY domain-containing protein, but the pseudogene serves primarily as a non-functional or regulatory genetic element[1][2][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on SPRY domain containing 4 pseudogene (SPRYD4 pseudogene).